{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:47:37Z","timestamp":1747154857928,"version":"3.40.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","amjmedsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.amjms.2018.10.009","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T13:45:49Z","timestamp":1540475149000},"page":"43-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["5-(3,3-Dimethyle-1-Triazeno) Imidazole-4-Carboxamide and Interleukin-2 Adjuvant Therapy in Resected High-Risk Primary and Regionally Metastatic Melanoma"],"prefix":"10.1016","volume":"357","author":[{"given":"Amitoj","family":"Gill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Gosain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Gragg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Bycroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-353X","authenticated-orcid":false,"given":"Shesh N.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Chesney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2018.10.009_bib0001","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0003","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0004","series-title":"N Engl J Med","article-title":"Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma","author":"Weber","year":"2017"},{"key":"10.1016\/j.amjms.2018.10.009_bib0005","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0006","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0007","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2001.19.5.1430","article-title":"High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group phase II trial E2696","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0008","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":"Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis","volume":"102","author":"Mocellin","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.amjms.2018.10.009_bib0009","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2011.41.3799","article-title":"Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma","volume":"30","author":"Eggermont","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0010","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2018.10.009_bib0011","series-title":"N Engl J Med","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","author":"Long","year":"2017"},{"key":"10.1016\/j.amjms.2018.10.009_bib0012","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0013","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"issue":"6 Suppl","key":"10.1016\/j.amjms.2018.10.009_bib0014","first-page":"S11","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update","volume":"1","author":"Atkins","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.amjms.2018.10.009_bib0015","first-page":"2775","article-title":"Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy","volume":"8","author":"O'Day","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.amjms.2018.10.009_bib0016","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","volume":"26","author":"Atkins","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3 Suppl","key":"10.1016\/j.amjms.2018.10.009_bib0017","first-page":"S9","article-title":"Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience","volume":"1","author":"Legha","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.amjms.2018.10.009_bib0018","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1200\/JCO.1998.16.5.1752","article-title":"Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma","volume":"16","author":"Legha","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0019","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.1994.12.8.1553","article-title":"Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma","volume":"12","author":"Atkins","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0020","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1002\/1097-0142(19930601)71:11<3520::AID-CNCR2820711110>3.0.CO;2-A","article-title":"A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma","volume":"71","author":"Flaherty","year":"1993","journal-title":"Cancer"},{"issue":"3 Suppl","key":"10.1016\/j.amjms.2018.10.009_bib0021","first-page":"S29","article-title":"Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma","volume":"1","author":"Thompson","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.amjms.2018.10.009_bib0022","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Statist Assoc"},{"key":"10.1016\/j.amjms.2018.10.009_bib0023","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/03610918.2011.560732","article-title":"Confidence intervals for survival probabilities: a comparison study","volume":"40","author":"Yuan","year":"2011","journal-title":"Commun Stat"},{"key":"10.1016\/j.amjms.2018.10.009_bib0024","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2013.53.1590","volume":"32","author":"Flaherty","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0025","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1002\/1097-0142(19810601)47:11<2556::AID-CNCR2820471107>3.0.CO;2-J","article-title":"DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) surgical adjuvant study COG PROTOCOL 7040","volume":"47","author":"Hill","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.amjms.2018.10.009_bib0026","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1200\/JCO.2003.07.116","article-title":"Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis","volume":"21","author":"Hauschild","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0027","series-title":"N Engl J Med","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","author":"Eggermont","year":"2018"},{"key":"10.1016\/j.amjms.2018.10.009_bib0028","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/COC.0b013e31827def82","article-title":"Adjuvant GM-CSF improves survival in high-risk stage IIIc melanoma: a single-center Study","volume":"37","author":"Grotz","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0029","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1200\/JCO.2000.18.8.1614","article-title":"Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor","volume":"18","author":"Spitler","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2018.10.009_bib0030","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2015.62.0500","volume":"33","author":"Lawson","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962918304075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962918304075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T04:50:47Z","timestamp":1546404647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962918304075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0002962918304075"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2018.10.009","relation":{},"ISSN":["0002-9629"],"issn-type":[{"type":"print","value":"0002-9629"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"5-(3,3-Dimethyle-1-Triazeno) Imidazole-4-Carboxamide and Interleukin-2 Adjuvant Therapy in Resected High-Risk Primary and Regionally Metastatic Melanoma","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2018.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}